Latest News

Cilta-cel therapy shows improved outcomes in earlier treatment lines for relapsed/refractory multiple myeloma, enhancing immune fitness and survival rates.

Lisaftoclax shows promising efficacy and safety in treating relapsed/refractory CLL/SLL, achieving a 62.5% response rate and 23.89 months progression-free survival.

A recent study reveals high rates of metastatic recurrence in adolescent and young adult cancer patients, emphasizing the need for tailored survivorship care.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

MVR-T3011 shows promising efficacy in treating high-risk, BCG-unresponsive bladder cancer, with high response rates and favorable safety profiles.

Silevertinib shows promising antitumor activity in NSCLC and plans for a phase 2 trial in glioblastoma, targeting unmet oncology needs.

Oncology and primary care unite to enhance patient care through improved communication and collaboration, addressing the challenges of siloed practices.

Discover the most anticipated abstracts in hematologic malignancies at the 2025 ASH Meeting, featuring groundbreaking studies and innovative therapies.

Recent study results highlight the critical impact of comorbidities on survival rates in patients with melanoma, emphasizing the need for integrated cancer care strategies.

TARA-002 shows promising efficacy and safety in treating BCG-naive non-muscle invasive bladder cancer, with high response rates and durability.

A novel treatment shows promise for leptomeningeal disease in breast cancer, offering hope with improved survival rates and symptom relief.

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative biomarker-driven therapies.

JANX007 shows promising efficacy and manageable safety in treating metastatic castration-resistant prostate cancer, with significant PSA reductions and durable responses.

New phase 2 trial results reveal safusidenib's potential to significantly improve outcomes for patients with IDH1-mutant gliomas, offering hope for durable responses.

Pirtobrutinib receives FDA traditional approval for relapsed CLL, showing significant progression-free survival benefits in clinical trials.

New trial data reveals IGV-001 enhances overall survival in glioblastoma patients, marking a potential breakthrough in treatment options.

Sacituzumab tirumotecan shows promising antitumor activity in advanced urothelial carcinoma, offering hope for patients with limited treatment options.

Ipatasertib shows promising efficacy in heavily pretreated patients with AKT1E17K mutations, highlighting its potential in diverse tumor types.

The FDA fast-tracks zotiraciclib for recurrent high-grade gliomas, offering hope for patients with IDH mutations and expanding treatment options.

Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.

Naxitamab combined with GM-CSF shows promising results in treating high-risk neuroblastoma, achieving high response rates and manageable safety profiles.

A clinical trial of the menin inhibitor DS-1594b in patients with relapsed leukemia has been terminated due to inefficacy, revealing safety challenges and insights for future therapies.

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

In a recent phase 2 trial, TQB2102 showed promising antitumor activity and safety as a neoadjuvant therapy for HER2-positive breast cancer.

Discover the most anticipated abstracts at the 67th ASH Annual Meeting and Exposition, showcasing groundbreaking research in hematologic malignancies and innovative treatments.

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

CLN-049 gains FDA fast track designation, offering hope for patients with relapsed/refractory AML through innovative immunotherapy solutions.

The FDA approves pegfilgrastim-unne, enhancing treatment options for cancer patients at risk of febrile neutropenia during chemotherapy.

The IsoPSA test revolutionizes prostate cancer diagnosis, enhancing risk assessment and reducing unnecessary biopsies for men with elevated PSA levels.